GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2007

Q-Med and Medy-Tox Join Forces to Develop Botulinum Toxin Products

  • Q-Med and Medy-Tox entered into an collaboration agreement for botulinum toxin-based biopharmaceuticals. Q-Med will develop and commercialize new generations of these products for both esthetic and therapeutic indications.

    Under the agreement, Q-Med will pay Medy-Tox milestones up to $8 million provided that specific targets are met. Medy-Tox is entitled to royalties on products developed by Q-Med that are based on its active pharmaceutical ingredients.

    Medy-Tox retains the right of first refusal regarding distribution in India, Thailand, Singapore, and South Korea of newly developed botulinum toxin products.

    In return for Medy-Tox’ support, Q-Med will provide an additional conditioned $3 million to help Medy-Tox expand its facilities in Ochang-myeon in South Korea.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?